Hi Sparkle - I think you did something very similar time me - I tried to cherry pick stocks Woodford was looking at. Bought Reneiron and sold for about the same.
Sorry to hear about your mum. If you are looking at stocks in PC have a gander at Oncosil. (Aussie). I'm about 10% down on it but holding on. Good news has happened (CE Mark).
Good to hear about investor making money - I have bought from £1.60 here but the clinical difference when you have overflowing ICU would appear to on good to ignore. Plus it shows it works against viruses so I can imagine Indication will go beyond covid. Then there is COPD.
UK based trial and motivation was to get it right. Randomised and blinded.
If submit to UK journal then I'd expect it to be treated fairly since some KOLs involved. Peer review will be peer reviewed in this case so it will be scrutinised.
Confidence intervals look good and given the low numbers is reassuring.
I'm assuming it will get published quickly albeit with the standard more trials needed - I expect these will be around the patients who would benefit most, combination with other products and dosing schedules.